Shares of genetic testing company Natera cratered 12.6% to $318.00 after the company posted a third-quarter loss far wider than Wall Street expected — even as its top line crushed estimates. The disconnect between booming revenue and stubborn losses forces a pointed question: can Natera grow fast enough to outrun its own spending?
Revenue Soared, but Losses Still Stung
Natera delivered $794 million in Q3 revenue, beating consensus estimates of $709.3 million by 11.9% on 34.1% year-over-year growth. Yet its GAAP loss of $0.42 per share missed the $0.27 analyst estimate by 56.4%. Wall Street rewarded the beat in every prior quarter this year; this time, the magnitude of the earnings miss overwhelmed the revenue story.
Spending Is Growing for a Reason — But It's Expensive
R&D expenses jumped 39.8% year over year , driven by a $25.8 million increase in headcount costs and a $24.7 million surge in lab and clinical trial expenses, including investments in early cancer detection. Management openly acknowledged on the earnings call that it has "accelerated a lot of investments" in pharma-specific offerings and operations "that drive both CapEx and operating expenses higher this year."
Total operating expenses hit $576.1 million, up 19.5% from a year ago — growing slower than revenue, a positive sign, but still producing a $68 million operating loss.
Oncology Is the Growth Engine Investors Are Paying For
Oncology test volumes exploded 60.9% year over year to roughly 339,500 tests , led by its blood-based cancer monitoring technology. Clinical cancer-monitoring units grew over 33,000 sequentially, the second straight quarter above 30,000. This is the franchise that justifies Natera's premium valuation — management targets $6 billion in revenue by 2029 — but it requires heavy upfront investment before it becomes consistently profitable.
Raised Guidance Signals Confidence, Not Caution
Natera lifted full-year 2026 revenue guidance by $140 million at the midpoint, now expecting $3.005–$3.035 billion. That is the third consecutive quarterly raise this year. Analysts still expect profitability to improve, forecasting full-year EPS to narrow from -$1.15 to -$0.61 , but today's miss undercuts that narrative.
The stock had run up 83% over the past year. At these levels, investors are paying not just for growth — which remains exceptional — but for a clear path to profits. Thursday's selloff is the market demanding receipts.